1383735-30-5

Basic information

• Product Name: Ethyl 1H-pyrazolo[4,3-b]p...
• Synonyms: Ethyl 1H-pyrazolo[4,3-b]pyridine-6-carboxylate
• CAS NO: 1383735-30-5
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.18666
• Mol File: 1383735-30-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 345.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.339±0.06 g/cm3(Predicted)
• PKA: 9.41±0.40(Predicted)
• CAS DataBase Reference: Ethyl 1H-pyrazolo[4,3-b]p...(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1H-pyrazolo[4,3-b]p...(1383735-30-5)
• EPA Substance Registry System: Ethyl 1H-pyrazolo[4,3-b]p...(1383735-30-5)

Safety Data

• Hazardous Substances Data: 1383735-30-5(Hazardous Substances Data)

Upstream product

• 1150617-54-1 6-bromo-1H-pyrazolo[4,3-b]pyridine 
• 541-41-3 chloroformic acid ethyl ester 
• 1383735-65-6 1-{6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl}ethan-1-one 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 1301214-71-0 N-(5-bromo-2-methyl-pyridin-3-yl)-acetamide 
• 914358-73-9 5-bromo-2-methylpyridin-3-ylamine 
• 911434-05-4 5-bromo-2-methyl-3-nitropyridine 
• 911434-04-3 2-(5-bromo-3-nitro-pyridin-2-yl)-malonic acid diethyl ester 
• 64-17-5 ethanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1383735-31-6 C₁₅H₁₂FN₃O₂ 
• 1383735-64-5 C₁₅H₁₆FN₃O₂ 
• 1383735-67-8 C₁₃H₁₀FN₃ 
• 1383735-34-9 C₁₆H₁₅ClFN₃O₃ 
• 1383733-69-4 1-(4-fluorophenyl)-4-[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butylcarbamoyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-6-carboxylic acid ethyl ester 
• 1383733-70-7 1-(4-fluorophenyl)-4-[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butylcarbamoyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-6-carboxylic acid 
• 1383733-71-8 1-(4-fluorophenyl)-l,5,6,7-tetrahydro-pyrazolo[4,3-b]pyridine-4,6-dicarboxylic acid 4-{[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butyl]-amide} 6-methylamide 

Relevant articles and documents

FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.